/

ALEC

Alector, Inc.Open

1.86−0.22 −10.82%USD

NasdaqGS · as of Oct 13, 15:49 ET · 15m delay

Open

2.08

Prev close

2.08

Day range

1.782.08

52-week range

1.093.40

Volume

2.27M0.78×

Mkt cap

207.12M

P/E ttm

—

Fwd P/E

-2.54

EPS ttm

-1.09

Div yield

0.00%

Earnings

—

From 52w high

−45.44%

Price Chart

Yahoo Finance · delayed

ALECOct 13, 2026O 2.08H 2.08L 1.77C 1.86−0.22 (−10.82%)Vol 2.27M

SMA 502.08
SMA 2002.01

1Y change −38.58% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ALEC Alector, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.49%
1 month: −13.32%
3 months: +33.45%
6 months: −23.03%
Year to date: +18.91%
1 year: −38.98%

Valuation & ownership

Market cap: 207.12M
Enterprise value: 92.21M
P/E (ttm): —
Forward P/E: -2.54
PEG ratio: —
Price / book: —
Price / sales (ttm): 14.94
EV / EBITDA: -0.78
EPS (ttm): -1.09
EPS (forward): -0.7317
Beta (5y monthly): 0.62
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 111.66M
Float: 84.94M
Short % of float: 5.83%
Short ratio (days): 4.35
Held by insiders: 9.52%
Held by institutions: 93.29%
Avg volume (3m): 2.91M
50-day average: 2.07
200-day average: 2.01
52-week change: −38.98%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 44.1
vs 50-day SMA: −10.75%
vs 200-day SMA: −7.79%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 11.66%
Realised vol (20d, ann.): 81.2%
From 52-week high: −45.44%
From 52-week low: +70.18%

ANR

Analyst Consensus

5 analysts

Consensus

Hold

2.57 on a 1 (strong buy) – 5 (sell) scale

Mean target

3.30

+77.90% implied

Low 1.00Median 3.00High 6.00

Recommendation trend

Now3 / 2 / 2
1m ago

DES

About Alector, Inc.

Yahoo Finance profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 103
Headquarters: South San Francisco, CA, United States
Website: alector.com
Officers: Dr. Arnon Rosenthal Ph.D. Co-Founder, CEO & Director
Mr. Neil Berkley M.B.A., M.S. CFO & Chief Business Officer

SEAS

Seasonality · ALEC

2019–2026 · monthly returns

Strongest month Dec +7.72%Weakest month Mar −11.72%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	21.2	28.6	-11.5	10.2	-8.9	-6.9	-24.9	49.7	-18.1	0.3			+18.9%
2025	-12.2	-1.2	-25.0	-2.4	10.8	5.3	6.4	57.7	26.0	-50.3	-9.5	17.3	−17.5%
2024	-25.3	16.9	-13.6	-15.6	-3.1	-7.7	32.2	-12.0	-11.7	5.6	-47.4	-27.0	−76.3%
2023	-4.4	-3.2	-27.5	6.6	12.7	-19.2	14.1	-20.6	18.9	-19.8	4.2	47.2	−13.5%
2022	-23.2	-0.1	-10.0	-32.6	-7.7	14.7	0.6	1.3	-8.6	-2.7	-7.7	8.7	−55.3%
2021	11.3	8.0	10.8	-3.2	-8.7	17.0	15.4	12.5	-15.6	-4.7	-5.0	0.0	+36.5%
2020	62.2	-1.6	-12.2	2.4	32.3	-25.3	-35.9	-17.5	-18.5	-10.7	39.3	15.4	−12.2%
2019			-4.4	6.1	-14.9	12.4	11.2	-22.1	-12.4	16.8	10.7	-7.6	−12.0%

INSD

Insider Activity · ALEC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

1.28M shares

Sells, 6 months

228.9K shares

Net shares

+1.05M

Net change in insider shares

+11.00%

Date	Insider	Transaction	Shares	Value
Sep 3, 2026	Wong-Sarad GraceOfficer	Sale at price 2.51 - 2.75 per share.	9.4K	$24.67K
Sep 2, 2026	Rosenthal ArnonChief Executive Officer	Sale at price 2.66 per share.	72.6K	$193.47K
Sep 2, 2026	Berkley Neil LindsayChief Financial Officer	Sale at price 2.66 per share.	29.3K	$77.95K
Aug 18, 2026	Rosenthal ArnonChief Executive Officer	Stock Gift at price 0.00 per share.	1.05M	—
Jul 8, 2026	Wong-Sarad GraceOfficer	Stock Award(Grant) at price 0.00 per share.	20K	—
Jun 16, 2026	Lavigne Louis J JrDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 16, 2026	Desouza Errol BDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 16, 2026	Scheller Richard HDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 16, 2026	Altmeyer MarkDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 16, 2026	Yaffe KristineDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 16, 2026	Hammond PaulaDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 16, 2026	Garofalo Elizabeth Amy M.D.Director	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Jun 2, 2026	Wong-Sarad GraceOfficer	Sale at price 1.88 - 1.97 per share.	9.2K	$17.81K
Jun 1, 2026	Rosenthal ArnonChief Executive Officer	Sale at price 1.97 per share.	87.2K	$172.19K
Jun 1, 2026	Berkley Neil LindsayChief Financial Officer	Sale at price 1.97 per share.	19.4K	$38.22K
May 31, 2026	Scheller Richard HDirector	Stock Award(Grant) at price 0.00 per share.	10.8K	—
Apr 15, 2026	Wong-Sarad GraceOfficer	Sale at price 2.65 per share.	1.8K	$4.82K
Mar 12, 2026	Rosenthal ArnonChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	116.2K	—
Mar 12, 2026	Berkley Neil LindsayChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	54.6K	—
Mar 9, 2026	Wong-Sarad GraceOfficer	Sale at price 2.65 per share.	1K	$2.65K

13F

Investors Holding ALEC

latest 13F filings of 29 followed managers

Investors holding ALEC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.9M	0.00%	935.17K	−27%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ALEC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ALEC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alector, Inc.

Seasonality · ALEC

Insider Activity · ALEC

Congress Trades · ALEC

Investors Holding ALEC

Investors Holding ALEC

Congress Trades · ALEC

Insider Activity · ALEC

Seasonality · ALEC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alector, Inc.

Financial Snapshot

Earnings & Dividends

News